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Summary
Dupilumab is the first biologic registered for the treatment of atopic dermatitis
(AD). We report on seven patients with AD presenting with a paradoxical head
and neck erythema that appeared 10–39 weeks after the start of dupilumab
treatment. The patients presented with a relatively sharply demarcated, patchy
erythema in the head and neck area that showed no or less scaling compared
with their usual eczema. Only one patient experienced symptoms of itch and
burning, although this was notably different from his pre-existent facial AD.
Except for a notable ‘red face’, eczema on other body parts had greatly
improved in six of the seven patients, with a mean numerical rating scale for
treatment satisfaction of 9 out of 10 at the time of biopsy. Treatment of the
erythema with topical and systemic drugs was unsuccessful. Despite the pres-
ence of this erythema, none of our patients discontinued dupilumab treatment.
Lesional skin biopsies showed an increased number of ectatic capillaries, and a
perivascular lymphohistiocytic infiltration in all patients. In addition, epidermal
hyperplasia with elongation of the rete ridges was observed in four patients,
resembling a psoriasiform dermatitis. Additional immunohistochemical stainings
revealed increased numbers of plasma cells, histiocytes and T lymphocytes.
Interestingly, spongiosis was largely absent in all biopsies. We report on
patients with AD treated with dupilumab developing a paradoxical erythema in
a head and neck distribution. Both clinically and histopathologically we found a
heterogeneous response, which was most suggestive of a drug-induced skin
reaction.
What’s already known about this topic?
• Dupilumab has proven to be an efficacious and effective treatment for atopic der-
matitis with an acceptable safety profile.
• The most frequently observed side-effects in patients with atopic dermatitis treated
with dupilumab are conjunctivitis, herpes infections and injection-site reactions.
What does this study add?
• For the first time, we report on patients with atopic dermatitis treated with dupilu-
mab who developed a paradoxical, mainly asymptomatic erythema in a head and
neck distribution.
• Histological examination of skin biopsies revealed a psoriasiform reaction pattern
suggestive of a drug-induced skin reaction.
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Dupilumab is the first biologic registered for treatment of
moderate-to-severe atopic dermatitis (AD). By binding to the
interleukin (IL)-4 receptor alpha chain, dupilumab blocks IL-4
and IL-13 signalling, thereby modulating the T helper (Th)2-
mediated inflammation in AD.1 In clinical trials, conjunctivitis,
herpes infections and injection-site reactions were found to be
the most frequently observed side-effects.1 Currently, only one
case of paradoxical, refractory erythema in a head and neck
distribution developing during dupilumab treatment has been
reported.2
Here we describe a series of seven patients with AD who
were treated with dupilumab and developed a paradoxical ery-
thema in a head and neck distribution, differing from their
usual AD lesions. We did not previously check systematically
for this erythema in our dupilumab-treated patients with AD
(n > 150). However, we increasingly seem to observe this
phenomenon. We recorded the medical history, patient- and
physician-reported outcome measures, and clinical symptoms,
and obtained lesional skin biopsies for histological examina-
tion.
Case report
The patient characteristics are summarized in Table 1. The
erythema appeared after at least 10 weeks of dupilumab treat-
ment, and patients had been treated with dupilumab for 12–
71 weeks at the time of biopsy. Concomitant treatment
included topical corticosteroids and topical calcineurin inhibi-
tors, but no systemic immunosuppressants. There were no rel-
evant (nonatopic, dermatological) comorbidities and the
patients did not use any other systemic drugs. Prior to dupilu-
mab treatment, six of the seven patients had experienced ery-
thematosquamous lesions in the head and neck area,
associated with symptoms of itching and burning in five of
these patients. The patients noted that the signs and symptoms
of the paradoxical erythema were different from their regular
eczema. Strikingly, six of the seven patients did not report any
symptoms of itch and burning in the head and neck area
during dupilumab treatment.
During dupilumab treatment, the patients presented with a
relatively sharply demarcated, patchy erythema in the head
and neck area that showed less or no scaling compared with
their usual eczema (Fig. 1a, b). Follicular accentuation was
absent. Only one patient who presented with scaling lesions
experienced symptoms of itch and burning, although they
were notably different from the pre-existent symptoms. Treat-
ment of the erythema with topical and systemic drugs, includ-
ing potent topical corticosteroids, topical calcineurin
inhibitors, emollients, antifungal medication, antibiotics, anti-
histamines and oral corticosteroids, was unsuccessful
(Table 1). Although the lesions did not respond to treatment
all patients continued dupilumab treatment.
All patients experienced a clinically relevant reduction of
the total Eczema Area and Severity Index (EASI) score
(Table S1; see Supporting Information). However, in all seven
patients, the disease severity scores increased again after
10–39 weeks of treatment. In the same period, all patients
gradually developed an erythema specifically in the head and
neck region, which was reflected by a disproportional increase
of the head and neck EASI subscore (Table S1). Despite the
development of this erythema, the mean numerical rating
scale for treatment satisfaction rated by the patients at time of
biopsy was still 9 on a 10-point scale.
Histopathological examination of lesional skin biopsies
(n = 7) included haematoxylin and eosin (Fig. 1c, d) and
immunohistochemical stainings for CD3, CD20, CD68, CD138
and CD117 (Table S2; see Supporting Information).
Histopathology showed epidermal hyperplasia with bulbous
elongated rete ridges, increased numbers of ectatic capillaries
in the papillary dermis and a moderate perivascular lympho-
cytic inflammation reminiscent of a psoriasiform dermatitis in
four patients (Fig. 1c, d; Table S2). Biopsies from the other
three patients also showed increased ectatic capillaries and
perivascular lymphocytic exocytosis, but no epidermal hyper-
plasia. Overall, small numbers of eosinophils were found, and
neutrophils and melanophages were largely absent. We found
normal numbers of mast cells (CD117), T cells (CD3) and his-
tiocytes (CD68). There were variable numbers of plasma cells
(CD138), but B cells (CD20) were largely absent. Surprisingly,
spongiosis was largely absent in all biopsies.
Discussion
We describe a paradoxical erythema in a head and neck distri-
bution that developed in patients with AD during dupilumab
treatment. Histopathology showed a psoriasiform hyperplasia
in four of seven patients, with ectatic capillaries in six of
seven. Interestingly, spongiosis was absent in five of the seven
patients. Although the histological findings could represent an
atypical manifestation of chronic AD, the clinical manifestation
with a sharply demarcated, patchy erythema and absence of
itch was not typical for AD.3 Although these patients were
very satisfied with their overall treatment result, it has been
shown that involvement of the face or neck is associated with
higher patient-perceived importance of almost or complete
skin clearance.4
The histopathology of acute AD lesions is characterized by
spongiosis and perivascular lymphocytic and eosinophilic
infiltrates.3 Subacute and chronic lesions show acanthosis,
sometimes in a psoriasiform pattern; hyper- and parakerato-
sis; fibrosis; spongiosis; dense infiltrates of mononuclear
cells; eosinophils and increased mast cells.3 Interestingly, we
found that most of these histopathological hallmarks of AD
were missing in the biopsies. Spongiosis and mononuclear,
mast cell and eosinophilic infiltrates were mostly absent,
confirming our clinical observation that these are not typical
AD lesions.
AD has been hypothesized to be a biphasic T-cell-driven
disease, with a predominance of Th2 cytokines in the acute
phase and increased expression of the Th1, Th17 and Th22
cytokines in the chronic phase.5 As dupilumab targets the IL-4
receptor alpha chain, it blocks the key signalling pathways for
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Th2 T-cell differentiation.1 Blocking the Th2 pathway could
hypothetically result in a shift towards a more Th1-, Th17-
and Th22-dominated response, resulting in the psoriasiform
reaction pattern that we observed.6 Fowler et al. recently
reported the development of psoriatic lesions during dupilu-
mab treatment in two patients,7 but in contrast to our find-
ings, they describe typical psoriasis lesions that were not
located in the head and neck region.
Table 1 Patient and clinical characteristics (n = 7)
Patient 1 2 3 4 5 6 7
Patient characteristics
Sex Male Female Male Male Male Male Male
Age (years) 28 29 26 19 58 35 46
Disease duration
(years)
16 29 26 19 52 35 46
Fitzpatrick skin type II III II II III II II
Asthma/allergic
rhinoconjunctivitis
+/+ +/+ /+ +/+ /+ +/+ +/+
ACDa +   + NA NA 
Occupation, hobbies Office job Office job Biologic crop
control,
soccer
Student Warehouse
worker
PE teacher,
tennis coach
Salesman
Previous systemic
immunosuppressants
CsA, MMF,
AZA, MTX,
APR, UST,
prednisone
CsA,
prednisone
CsA,
prednisone
CsA, AZA,
prednisone
CsA, MTX,
prednisone
CsA, MTX,
prednisone
CsA, MTX,
prednisone
Clinical characteristics
Onset of erythema
(weeks of
dupilumab
treatment)
39 28 16–29 16–28 10–22 20 11
Treatment duration
at biopsy (weeks)
49 53 42 51 22 71 12
Symptoms before
dupilumab
Erythema + + + +  + +
Scaling + + + +  + +
Itch +  + +  + +
Burning sensation +  + +  + +
Symptoms of
paradoxical
erythema
Erythema + + + + + + +
Scaling +      
Itch +b      
Burning sensation +b      
Influence of:
Ultraviolet   +    
Alcohol  NA     
Smoking  NA NA NA NA  
Retesting ACDc NA   NA NA + NA
Topicals
prescriptionsd,e
Class 3–4 TCS,
TCI,
emollients,
ivermectin
Class 3–4 TCS,
emollients
Class 3–4 TCS,
emollients,
fusidic acid
Class 3–4 TCS,
emollients
Class 3–4 TCS,
emollients
Class 3 TCS,
TCI,
emollients
Class 5 TCS
Systemic
prescriptionsd
Prednisone Prednisone Antifungals,
antibiotics,
antihistamine
Antihistamine None None None
ACD, allergic contact dermatitis; APR, apremilast; AZA, azathioprine; CsA, ciclosporin A; MMF, mycophenolate mofetil; MTX, methotrexate;
NA, not applicable; PE, physical education; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids; UST, ustekinumab. aEpicutaneous
patch-proven ACD, tested prior to dupilumab treatment. bSymptoms were notably different from the pre-existing situation. cEpicutaneous
patch-proven ACD, (re)tested after onset of erythema. dPrescribed for head and neck erythema. eWorld Health Organization classification for
topical corticosteroids.
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Because we found this paradoxical erythema only in a typi-
cal head and neck distribution, we also considered allergic
contact dermatitis (ACD), Malassezia furfur-associated head and
neck dermatitis, Demodex-associated rosacea-like dermatosis, and
a drug-induced photosensitivity reaction. Patch testing for
ACD was performed in three patients during dupilumab treat-
ment, but only one patient showed positive patch tests, to
lanolin and cocamidopropyl betaine. However, avoidance of
the allergens did not improve this erythema and the
histopathological findings were not suggestive of ACD.8
It has been suggested that (co)sensitization to the human
and/or fungal (including Malassezia spp.) enzyme superoxide
dismutase might play an important role in the pathogenesis of
AD and associated head and neck dermatitis.9,10 In murine
models it was recently shown that Malassezia induces Th17-
driven inflammation.11 In patients with AD treated with
dupilumab, IL-4 receptor blockade might facilitate a Th17-
dominated response. However, in these mouse models, Malas-
sezia also triggered massive infiltration of neutrophils and
monocytes in the skin, which we did not find in the biopsies
of our patients. Increased Th17 cytokine expression could also
be in favour of Demodex colonization, which is associated with
rosacea.12 However, the clinical presentation in our patients
was not typical for rosacea. In addition, histological features
of rosacea were absent.13
The distribution of the lesions in our patients was also
suggestive of a drug-induced photosensitivity reaction, but
none of our patients was using a known photosensitive drug,
and influence of ultraviolet radiation on the erythema was
denied.14 Furthermore, the most common histological pattern
found in drug-induced photosensitivity reactions is a vacuo-
lar interface dermatitis,15 which was not seen in our
patients.
We speculate that this paradoxical head and neck erythema
is a dupilumab-induced skin reaction. From personal commu-
nication with other experts in AD we know that others have
also observed this phenomenon. This emphasizes the impor-
tance of daily-practice registries to gain better insights in the
incidences of this phenomenon. Also, further research is
needed to elucidate the underlying pathophysiological process.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Table S1 Disease severity (sub)scores at baseline and during
dupilumab treatment.
Table S2 Histopathological findings in lesional skin
biopsies.
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